Anti-tumour Activity and Toxicological Studies of Combination Treatment of and Gemcitabine on Pancreatic Xenograft Model

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Sep 26

PMID 36157930

Authors

Ashwaq Hamid Salem Yehya

Ayappa V Subramaniam

Muhammad Asif

Gurjeet Kaur

Amin M S Abdul Majid

Chern Ein Oon

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer is the most aggressive cancer type. Gemcitabine is the first line chemo-drug used for pancreatic cancer but exerts a broad spectrum of organ toxicities and adverse effects in patients.

Aim: To evaluate the anti-tumour activity and toxicological effects of extract formulation (ID: C5EOSEW5050ESA trademarked as Nuva-static), and gemcitabine combination on pancreatic xenograft model.

Methods: Mice were randomly divided into six groups of 6 mice each ( = 6) and given different treatments for 28 d. The study design consisted of a 2 x 3 factorial treatment structure, with gemcitabine (yes/no) by oral (at 1200 and 400 mg/kg per day). Human pancreatic cancer cells were injected subcutaneously into the flanks of athymic nude mice. C5EOSEW5050ESA (200 or 400 mg/kg per day) was administered orally, while gemcitabine (10 mg/kg per 3 d) was given intraperitoneally either alone or in combination treatment. Histopathological analyses of vital organs, tumour tissues, and incidence of lethality were analysed. Analyses of tumour necrosis and proliferation were determined by haematoxylin-eosin staining and immunohistochemistry for Ki-67, respectively.

Results: No signs of toxicity or damage to vital organs were observed in all treatment groups compared to the untreated group. C5EOSEW5050ESA at 200 mg/kg and gemcitabine combination had no additive antitumor effects compared to a single treatment. Remarkably, a comparably greater response in a reduction in tumour growth, Ki-67 protein expression, and necrosis was demonstrated by 400 mg/kg of C5EOSEW5050ESA and gemcitabine combination than that of the individual agents.

Conclusion: These results highlighted the synergistic activity of C5EOSEW5050ESA with gemcitabine to reduce pancreatic tumour growth in mice compared to a single treatment. Thus, this study provides valuable insights into using C5EOSEW5050ESA as a complementary treatment with gemcitabine for pancreatic cancer.

References

Ahamed M, Aisha A, Nassar Z, Siddiqui J, Ismail Z, Omari S . Cat's whiskers tea (Orthosiphon stamineus) extract inhibits growth of colon tumor in nude mice and angiogenesis in endothelial cells via suppressing VEGFR phosphorylation. Nutr Cancer. 2011; 64(1):89-99. DOI: 10.1080/01635581.2012.630160. View

Yan X, Li Y, Yu H, Wang W, Wu C, Yang Y . Epigallocatechin-3-gallate inhibits HO-induced apoptosis in Mouse Vascular Smooth Muscle Cells via 67kD Laminin Receptor. Sci Rep. 2017; 7(1):7774. PMC: 5552808. DOI: 10.1038/s41598-017-08301-6. View

Looi C, Chung F, Leong C, Wong S, Rosli R, Mai C . Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res. 2019; 38(1):162. PMC: 6463646. DOI: 10.1186/s13046-019-1153-8. View

Hoster E, Rosenwald A, Berger F, Bernd H, Hartmann S, Loddenkemper C . Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016; 34(12):1386-94. DOI: 10.1200/JCO.2015.63.8387. View

Xue R, Fang Z, Zhang M, Yi Z, Wen C, Shi T . TCMID: Traditional Chinese Medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res. 2012; 41(Database issue):D1089-95. PMC: 3531123. DOI: 10.1093/nar/gks1100. View

Yehya A, Asif M, Majid A, Oon C . Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancer. Biomed J. 2022; 44(6):694-708. PMC: 8847836. DOI: 10.1016/j.bj.2020.05.015. View

Alissa E . Medicinal herbs and therapeutic drugs interactions. Ther Drug Monit. 2014; 36(4):413-22. DOI: 10.1097/FTD.0000000000000035. View

Shukla S, Purohit V, Mehla K, Gunda V, Chaika N, Vernucci E . MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 2017; 32(1):71-87.e7. PMC: 5533091. DOI: 10.1016/j.ccell.2017.06.004. View

Mahmood H, Khan I, Asif M, Khan R, Asghar S, Khalid I . In vitro and in vivo evaluation of gellan gum hydrogel films: Assessing the co impact of therapeutic oils and ofloxacin on wound healing. Int J Biol Macromol. 2020; 166:483-495. DOI: 10.1016/j.ijbiomac.2020.10.206. View

10.

Feres C, Madalosso R, Rocha O, Leite J, Guimaraes T, Toledo V . Acute and chronic toxicological studies of Dimorphandra mollis in experimental animals. J Ethnopharmacol. 2006; 108(3):450-6. DOI: 10.1016/j.jep.2006.06.002. View

11.

Vogl U, Andalibi H, Klaus A, Vormittag L, Schima W, Heinrich B . Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. BMC Cancer. 2019; 19(1):28. PMC: 6325849. DOI: 10.1186/s12885-018-5240-6. View

12.

Yehya A, Asif M, Petersen S, Subramaniam A, Kono K, Majid A . Angiogenesis: Managing the Culprits behind Tumorigenesis and Metastasis. Medicina (Kaunas). 2018; 54(1). PMC: 6037250. DOI: 10.3390/medicina54010008. View

13.

Tanzeem M, Asghar S, Khalid S, Asif M, Ullah M, Khan I . Clove oil based co-surfactant free microemulsion of flurbiprofen: Improved solubility with ameliorated drug-induced gastritis. Pak J Pharm Sci. 2020; 32(6(Supplementary)):2787-2793. View

14.

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

15.

Shafaei A, Esmailli K, Farsi E, Aisha A, Abul Majid A, Ismail Z . Genotoxicity, acute and subchronic toxicity studies of nano liposomes of Orthosiphon stamineus ethanolic extract in Sprague Dawley rats. BMC Complement Altern Med. 2015; 15:360. PMC: 4604773. DOI: 10.1186/s12906-015-0885-z. View

16.

Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z . The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. 2015; 9(1):16-34. DOI: 10.5582/bst.2015.01019. View

17.

Mohamed E, Lim C, Ebrika O, Asmawi M, Sadikun A, Yam M . Toxicity evaluation of a standardised 50% ethanol extract of Orthosiphon stamineus. J Ethnopharmacol. 2010; 133(2):358-63. DOI: 10.1016/j.jep.2010.10.008. View

18.

Yehya A, Asif M, Kaur G, Hassan L, Al-Suede F, Majid A . Toxicological studies of (Misai Kucing) standardized ethanol extract in combination with gemcitabine in athymic nude mice model. J Adv Res. 2018; 15:59-68. PMC: 6300433. DOI: 10.1016/j.jare.2018.05.006. View

19.

Tabana Y, Al-Suede F, Ahamed M, Dahham S, Ahmed Hassan L, Khalilpour S . Cat's whiskers (Orthosiphon stamineus) tea modulates arthritis pathogenesis via the angiogenesis and inflammatory cascade. BMC Complement Altern Med. 2016; 16(1):480. PMC: 5122152. DOI: 10.1186/s12906-016-1467-4. View

20.

Fantini M, Benvenuto M, Masuelli L, Frajese G, Tresoldi I, Modesti A . In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment. Int J Mol Sci. 2015; 16(5):9236-82. PMC: 4463587. DOI: 10.3390/ijms16059236. View